Startseite
English
Erweiterte Suche
Durchblättern nach ...
Publikationen im Überblick
Ansprechpartner
Hilfe
Verlagsversion
DOI
PMC
 |
Open Access Gold |
|
möglich sobald bei der ZB eingereicht worden ist.
On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.
J. Immunother. Cancer 8:e001145 (2020)
The present review summarizes up-to-date evidence addressing the frequently discussed clinical controversies regarding the use of immune checkpoint inhibitors (ICIs) in cancer patients with viral infections, including AIDS, hepatitis B and C, progressive multifocal leukoencephalopathy, influenza, and COVID-19. In detail, we provide available information on (1) safety regarding the risk of new infections, (2) effects on the outcome of pre-existing infections, (3) whether immunosuppressive drugs used to treat ICI-related adverse events affect the risk of infection or virulence of pre-existing infections, (4) whether the use of vaccines in ICI-treated patients is considered safe, and (5) whether there are beneficial effects of ICIs that even qualify them as a therapeutic approach for these viral infections.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Review
Schlagwörter
Immune Evation ; Review ; T-lymphocytes ; Tumor Escape ; Vaccination; Progressive Multifocal Leukoencephalopathy; Lung-cancer; Therapy; Immunopathology; Immunotherapy; Exhaustion; Expression; Blockade; Defines
ISSN (print) / ISBN
2051-1426
e-ISSN
2051-1426
Zeitschrift
Journal for ImmunoTherapy of Cancer
Quellenangaben
Band: 8,
Heft: 2,
Artikelnummer: e001145
Verlag
BioMed Central
Verlagsort
London
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Institut(e)
Institute of Stem Cell Research (ISF)